Patents Assigned to Pfizer
  • Biotin intermediates
    Patent number: 4709044
    Abstract: In the synthesis of biotin and decarboxybiotin, a more direct method for the conversion of 1,3-diacyl-4-(bromomethyl)-5-[(5-alkoxycarbonylpentanoyl) or hexanoyl]-4-imidazolin-2-ones to 1,3-diacyl-4-[(4-alkoxybutanoyl) or pentanoyl]-1H,3H-thieno(3,4-b)imidazol-2-one via the Bunte salt of the formula ##STR1## wherein R is (C.sub.1 -C.sub.5)alkanoyl or (C.sub.2 -C.sub.5)alkoxycarbonyl, X is methyl or (C.sub.2 -C.sub.5)alkoxycarbonyl and Y is an alkali metal.
    Type: Grant
    Filed: May 23, 1986
    Date of Patent: November 24, 1987
    Assignee: Pfizer Inc.
    Inventor: Constantine Sklavounos
  • Enhanced hydrocarbon recovery by permeability modification with phenolic gels
    Patent number: 4708974
    Abstract: Hydrocarbon recovery from subterranean reservoirs that are penetrated by either injector or producer wells is enhanced by selective permeability modification of the strata of the reservoir with gel-forming phenolic compositions. The injection of the phenolic composition follows a pH sequence specific to the reservoir environment which allows emplacement of the gel-forming composition the desired distance away from the wellbore and production of a uniform gel throughout the treated hydrocarbon-bearing reservoir. The permeability of a treated subterranean reservoir can be restored by treatment of the reservoir with either aqueous hypochlorite or mineral acid.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: November 24, 1987
    Assignee: Pfizer Inc.
    Inventors: Ping W. Chang, Gordon D. Gruetzmacher, Clifford N. Meltz, Rocco A. Totino
  • Drilling fluid additive containing high pyruvate xanthan
    Patent number: 4707281
    Abstract: A drilling fluid additive comprises high pyruvate xanthan and locust bean gum in a weight ratio of about 40:60 to 80:20. The additive increases the viscosity of the drilling fluid at low shear, has improved thermal stability, and increases the capacity of the fluid to suspend high density weighting materials.
    Type: Grant
    Filed: June 3, 1985
    Date of Patent: November 17, 1987
    Assignee: Pfizer Inc.
    Inventors: James W. Miller, John J. O'Neill
  • 19-epi-dianemycin as an anticoccidial and antibacterial agent
    Patent number: 4707493
    Abstract: Antibiotic 19-epi-dianemycin, process for its preparation by fermenting a new strain of Streptomyces hygroscopicus, and isolation from the fermentation broth; and its use as an anticoccidial agent and antibacterial agent against gram-positive bacteria.
    Type: Grant
    Filed: November 17, 1986
    Date of Patent: November 17, 1987
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, John C. Ruddock, Junsuke Tone
  • Wire injection nozzle
    Patent number: 4705261
    Abstract: An injection nozzle for the addition of an agent in wire form directly into the interior of a molten material includes a tip having an axial bore with a terminal opening through which the wire exits the nozzle, the terminal opening having a cross section in the form of a star.
    Type: Grant
    Filed: November 28, 1986
    Date of Patent: November 10, 1987
    Assignee: Pfizer Inc.
    Inventor: Emil J. Wirth, Jr.
  • Composite material for induction heating
    Patent number: 4705727
    Abstract: A composite material comprising a layer of ferritic stainless steel of up to 0.005 inches thickness covered on both sides by a layer of austenitic stainless steel of up to 0.005 inches thickness and suitable for induction heating. A second composite material comprising the material above further bonded to an aluminum layer and another layer of austenitic stainless steel. Cookware made of both types of composite material.
    Type: Grant
    Filed: October 11, 1985
    Date of Patent: November 10, 1987
    Assignee: Pfizer Inc.
    Inventor: James R. Hunter
  • Drainage device with diverted gas flow path
    Patent number: 4704106
    Abstract: A drainage device has a collection chamber for receiving liquids and gases from the body of a patient, an underwater seal chamber and a one-way outflow valve. A partition extending across a portion of the device forms the underwater seal chamber, which prevents the flow of atmospheric air from the device into the pleural cavity of the patient, above the partition and the collection chamber below it. The underwater seal is created at the lower end of an extension connected to the inlet to the device by liquids drained from the patient. The one-way outflow valve communicates with a trap chamber for collecting liquids inadvertently conducted toward the valve. The trap chamber is closed off from the underwater seal chamber but is connected to the collection chamber by means of a passageway through a wall separating the trap and collection chambers.
    Type: Grant
    Filed: August 8, 1986
    Date of Patent: November 3, 1987
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: William H. Shave, Joseph R. Williams
  • Process for sultamicillin intermediate
    Patent number: 4704456
    Abstract: An improved process for the preparation of the chloromethyl ester of sulbactam (chloromethyl penicillanate 1,1-dioxide), an intermediate in the synthesis of sultamicillin (the mixed methanediol ester of sulbactam and ampicillin).
    Type: Grant
    Filed: November 22, 1985
    Date of Patent: November 3, 1987
    Assignee: Pfizer Inc.
    Inventor: Richard C. Adams
  • Long-acting matrix tablet formulations
    Patent number: 4704284
    Abstract: A pharmaceutical tablet which releases an initial burst of therapeutic agent and thereafter releases the agent at an essentially constant rate comprising an acid soluble therapeutic agent in an insoluble matrix, the tablet containing an acid insoluble, base soluble pharmaceutically acceptable component selected from polymers and fatty acids, a pharmaceutically acceptable organic acid and at least one pharmaceutically acceptable excipient, the component and the acid each being present in an amount of from about 1-25 percent by weight of the total composition.
    Type: Grant
    Filed: August 12, 1982
    Date of Patent: November 3, 1987
    Assignee: Pfizer Inc.
    Inventors: Morgan L. Beatty, Wayne A. Boettner
  • Processes and intermediates for sorbinil
    Patent number: 4704461
    Abstract: Chiral sorbinil intermediates of the formula ##STR1## wherein R is hydrogen or benzyloxycarbonyl and Y is hydroxy or amino, processes therefor, and processes for the conversion thereof to sorbinil.
    Type: Grant
    Filed: February 14, 1986
    Date of Patent: November 3, 1987
    Assignee: Pfizer Inc.
    Inventors: Berkeley W. Cue, Jr., Bernard S. Moore
  • Hypoglycemic thiazolidinediones
    Patent number: 4703052
    Abstract: Hypoglycemic 2,3-dihydro-5-benzo[b]furanyl-2,3-dihydro-5-benzo[b]thienyl-, 3,4-dihydro(2H)-6-benzopyranyl- and 6-thiochromanyl-thiazolidine-2,4-diones and pharmaceutically acceptable salts thereof, method for their use in treatment of hyperglycemic animals and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 29, 1986
    Date of Patent: October 27, 1987
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Gerald F. Holland, Mickael R. Johnson, Robert A. Volkmann
  • 1,1-bis(p-fluorophenyl)urea
    Patent number: 4698444
    Abstract: 1,1-Di(p-fluorophenyl)urea, 2-carbobenzoxy-8-fluoro-5-(p-fluorophenyl)-2,3,4,5-tetrahydro-1H-pyrido[4, 3-b]indole, an efficient process for converting the former to the latter, further comprising conversion of the latter to 8-fluoro-5-(p-fluorophenyl)-2-[4-(p-fluorophenyl)-4-hydroxybutyl)]-2,3,4,5 -tetrahydro-1H-pyrido[4,3-b]indole (flutroline) or to 8-fluoro-5-(p-fluorophenyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (an alternative flutroline intermediate).
    Type: Grant
    Filed: December 17, 1985
    Date of Patent: October 6, 1987
    Assignee: Pfizer Inc.
    Inventor: Stephen S. Massett
  • Hypoglycemic 5-substituted oxazolidine-2,4-diones
    Patent number: 4695634
    Abstract: Hypoglycemic 5-furyl and 5-thienyl derivatives of oxazolidine-2,4-dione and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; and intermediates useful in the preparation of said compounds.
    Type: Grant
    Filed: August 6, 1986
    Date of Patent: September 22, 1987
    Assignee: Pfizer Inc.
    Inventor: Rodney C. Schnur
  • Tricyclic oxindole antiinflammatory agents
    Patent number: 4695571
    Abstract: Tricyclic oxindole carboxamides, prepared by (a) reaction of an isocyanate with the basic ring system or (b) ammonolysis of a corresponding alkyl ester, are non-steroidal antiinflammatory agents useful in the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: April 2, 1986
    Date of Patent: September 22, 1987
    Assignee: Pfizer Inc.
    Inventor: Lawrence S. Melvin
  • 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
    Patent number: 4695626
    Abstract: 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate ester intermediates useful for the synthesis of penems.
    Type: Grant
    Filed: July 29, 1986
    Date of Patent: September 22, 1987
    Assignee: Pfizer Inc.
    Inventor: Katherine E. Brighty
  • Dual catalyst sequential method for production of sorbitol from hydrolyzed starch solution
    Patent number: 4694113
    Abstract: A process for production of sorbitol from 50-98.5 DE hydrolyzed starch solution by hydrogenation over a nickel catalyst at a pH of from 3.0 to 7.0, 120.degree. to 160.degree. C. and 500 to 2000 psig (35 to 140 Bars) until the reducing sugar value is below 5 percent; removal of nickel catalyst, acidification to pH 1.0 to 2.5 and hydrogenation of the acidified solution over a ruthenium catalyst, 100.degree. to 180.degree. C. and 500 to 2000 psig, until hydrogen uptake is substantially complete, and removal of the ruthenium catalyst.
    Type: Grant
    Filed: June 4, 1986
    Date of Patent: September 15, 1987
    Assignee: Pfizer Inc.
    Inventors: George J. Gauthier, John D. Miceli
  • 2H-1,2-benzothiazine derivatives
    Patent number: 4694080
    Abstract: Certain substituted-4-hydroxy-(or 4-acyloxy-)2H-1,2-benzothiazine 1,1-dioxides having at the 3-position a 2-substituted-1,3,4-oxadiazol-5-yl, a 2-substituted-tetrazol-5-yl or a 1-substituted-tetrazol-5-yl group useful as selective 5-lipoxygenase pathway inhibitors; and methods for their preparation.
    Type: Grant
    Filed: March 19, 1986
    Date of Patent: September 15, 1987
    Assignee: Pfizer Inc.
    Inventors: Susumu Nakanishi, Isao Nagakura
  • Imidazolidinone precursors for the preparation of biotin
    Patent number: 4694087
    Abstract: A novel process is described for preparation of biotin comprising preparation of substituted 3H, 5H-imidazo[1,5c]tetrahydro thiazoles by contacting the boron trifluoride adduct of an appropriate thiazoline with the metallic derivative of an ester enolate, reducing the ester, hydrolyzing the thiazolidine moiety and hydrolyzing or oxidizing the resultant compound. Intermediates obtained in the preparation of biotin by the above process and alternate procedures for preparing said intermediates are also presented. A novel process for preparation of d-biotin is also given.
    Type: Grant
    Filed: September 22, 1986
    Date of Patent: September 15, 1987
    Assignee: Pfizer Inc.
    Inventor: Robert A. Volkmann
  • Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
    Patent number: 4690943
    Abstract: Certain novel 2-oxindole compounds, having an acyl substituent at both the 1-position and the 3-position, are inhibitors of the cyclooxygenase (CO) and lipoxygenase (LO) enzymes, and are useful as analgesic agents and antiinflammatory agents in mammalian subjects. These 1,3-diacyl-2-oxindole compounds are of particular value for acute administration for ameliorating pain in human patients recovering from surgery or trauma, and also for chronic administration to human subjects for alleviating the symptoms of chronic diseases such as rheumatoid arthritis and osteoarthritis.
    Type: Grant
    Filed: June 20, 1985
    Date of Patent: September 1, 1987
    Assignee: Pfizer Inc.
    Inventor: Saul B. Kadin
  • Hypoglycemic 5-substituted oxazolidine 2,4-diones
    Patent number: 4689336
    Abstract: Hypoglycemic 5-chromanyl, 2,3-dihydro-5-benzo[b]-furanyl, 5-pyridyl, 5-quinolyl, 5-pyrrolyl, 5-indolyl, 5-thiazolyl, 5-oxazolyl, 5-isothiazolyl and 5-isoxazolyl oxazolidine-2,4-diones and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hyperglycemic animals therewith; and intermediates useful in the preparation of said compounds.
    Type: Grant
    Filed: October 3, 1985
    Date of Patent: August 25, 1987
    Assignee: Pfizer Inc.
    Inventor: Rodney C. Schnur